×
Customize
?
Start
Cancer Types
Quick Links
Events
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Liver Cancer
Beth Fand Incollingo
The results of an ongoing study designed to reveal genetic characteristics linked with the development of cholangiocarcinoma could pave the way for more accurate prognoses, as well as new treatments.
Beth Fand Incollingo
A survey administered by pharmaceutical company Incyte and the nonprofit Cholangiocarcinoma Foundation found that patients with bile duct cancer face more than a dozen symptoms or treatment-related side effects that negatively affect their daily lives.
Andrea Wilson Woods
After losing the sister she raised to an aggressive type of liver cancer, one woman has devoted herself to stamping out the disease.
Brielle Benyon
U.S. Supreme Court Justice Ruth Bader Ginsburg, 87, has announced that she is currently undergoing chemotherapy for a cancer recurrence.
Jessica Skarzynski
On the importance of finding more potent and well-tolerated therapies in hepatocellular carcinoma, Dr. Bruno Sangro explains: “The wider the spectrum of choices, the better we will be able to treat our patients.”
Jessica Skarzynski
When it comes to hepatocellular carcinoma (HCC), doctors have a handful of treatment options at their disposal. But how do they decide what’s best?
Michele Wheeler
Bill Beckett
Ryan McDonald
The Food and Drug Administration approved the combination of Tecentriq and Avastin in patients with unresectable or metastatic hepatocellular carcinoma, making it the first immunotherapy regimen to be approved for this cancer type.
Debu Tripathy, M.D.
In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.